Switch off inflammation in spleen cells with CD40-targeted PLGA nanoparticles containing dimethyl fumarate

Colloids Surf B Biointerfaces. 2021 Dec:208:112091. doi: 10.1016/j.colsurfb.2021.112091. Epub 2021 Sep 1.

Abstract

The purpose of this study was designing and synthesizing a PLGA formulation targeted with anti-CD40 monoclonal antibody, which has suitable physicochemical properties as a dimethyl fumarate (DMF) drug delivery system having minimal cytotoxicity. Therefore, this research was performed to determine the effect of anti-CD40mAb-DMF-NPs on the expression of IL-1β, IL-6 and TNF-α cytokine genes in mouse splenocytes. The toxicity of different groups, namely free PLGA, free DMF, DMF-containing PLGA, anti-CD40mAb-DMF-NPs, was evaluated by MTT assay. PLGA formulations conjugated with mAbCD40 were loaded with DMF drug that showed little cytotoxic effect against mouse splenocytes. QRT-PCR method was subsequently used to assess the effect of the mentioned groups on the expression of IL-1β, TNF-α and IL-6 genes. After treatment of the cells with DMF alone or with polymer carriers, the expression of IL-1β, IL-6 and TNF-α cytokine genes was significantly reduced. The decrease in expression was markedly higher in the antibody-targeted nanoparticles group relative to other treatment groups. Our results in this area are promising and provide a good basis for further future studies in this regard.

Keywords: DMF; Multiple sclerosis; PLGA; Spleen cells; mAbCD40.

MeSH terms

  • Animals
  • Dimethyl Fumarate* / pharmacology
  • Drug Carriers
  • Drug Delivery Systems
  • Inflammation
  • Mice
  • Nanoparticles*
  • Spleen

Substances

  • Drug Carriers
  • Dimethyl Fumarate